Track 12: CAR T-cell therapy
In CAR T-cell therapy, T cells are extracted from the patient's blood and altered in the laboratory by adding a gene for a receptor (known as a chimeric antigen receptor, or CAR), which aids the T cells in adhering to a particular cancer cell antigen. The patient is subsequently given their CAR T cells back.
Each CAR is created for a particular cancer's antigen since many malignancies have various antigens. For instance, the cancer cells in some types of leukaemia or lymphoma express the antigen CD19. The CAR T-cell treatments used to treat these tumours are designed to bind to the CD19 antigen and will not be effective against tumours lacking this antigen.
Related Conference of Track 12: CAR T-cell therapy
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Track 12: CAR T-cell therapy Conference Speakers
Recommended Sessions
- Track 10: Cellular Therapies
- Track 11: Advanced Gene Therapeutics
- Track 12: CAR T-cell therapy
- Track 13: Cancer Therapies
- Track 14: Nano-Therapy
- Track 15: Human Gene Therapy
- Track 16: Diabetes Gene Therapy
- Track 17: Molecular Epigenetics
- Track 18: Genetic Vaccines
- Track 19: Clinical Trials and Research in Cell and Gene Therapies
- Track 1: Cell Science and Stem Cell Research
- Track 20: Skin cell therapy
- Track 21: HIV gene therapy
- Track 22: Cell Therapy in Pulmonology
- Track 2: Stem Cell Therapies
- Track 3: Cell Culture and Bioprocessing
- Track 4: Viral gene therapy
- Track 5: Stem Cell in Drug Development
- Track 6: Nanotechnology in Stem Cell
- Track 7: Stem Cell in Cardiovascular Disease
- Track 8: Novel Stem Cell Therapy
- Track 9: Stem cell engineering
Related Journals
Are you interested in
- 3D Bioprinting, Organ Fabrication & Bioartificial Tissues - Stem Cell 2026 (Netherlands)
- Aging Biology, Longevity Science & Cellular Rejuvenation - Stem Cell 2026 (Netherlands)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioinformatics, AI Models & Predictive Regeneration - Stem Cell 2026 (Netherlands)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Stem Cells & Targeted Therapeutics - Stem Cell 2026 (Netherlands)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiac, Vascular & Musculoskeletal Regeneration - Stem Cell 2026 (Netherlands)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Clinical Translation of Stem Cell Therapies - Stem Cell 2026 (Netherlands)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Commercialization, Biobanking & Industry Innovations - Stem Cell 2026 (Netherlands)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Ethical, Regulatory & Quality Control Frameworks - Stem Cell 2026 (Netherlands)
- Exosomes, Extracellular Vesicles & Cell-Free Therapeutics - Stem Cell 2026 (Netherlands)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Gene Editing, CRISPR Therapies & Regenerative Genomics - Stem Cell 2026 (Netherlands)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Regeneration in Neurodegenerative & Spinal Cord Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Approaches in Diabetes & Metabolic Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Immunology & Immune Modulation - Stem Cell 2026 (Netherlands)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Engineering & Cellular Reprogramming - Stem Cell 2026 (Netherlands)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Tissue Engineering, Biomaterials & Smart Scaffolds - Stem Cell 2026 (Netherlands)
